Back to search results

Personalized Accelerated ChemoRadiation (PACER) for Lung Cancer

This study is looking at a treatment called hypofractionated accelerated radiation therapy (HART) for people with locally advanced lung cancer. This treatment involves giving radiation in fewer, stronger doses over a shorter period. You may be able to join if you have non-small cell lung cancer or small cell lung cancer that your doctors plan to treat with radiation and chemotherapy. The study will look at whether this treatment causes side effects in the lungs or esophagus (the tube that connects your throat to your stomach). The study plans to enroll 45 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 45 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main side effects will be measured at 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06080061

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
Stanford University
~45 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:Hypofractionated accelerated radiation therapy

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose limiting pulmonary and esophageal toxicity
Measured over 9 months

Conditions

Lung Cancer

Explore related trials

Lung Non-Small Cell CarcinomaLung Small Cell CarcinomaSolid Neoplasm

NCT06080061

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Stanford Cancer Center South Bay

    San Jose, Californiastudy coordinator listed

    Recruiting

  • Stanford University

    Palo Alto, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joseph A Jaoude, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Aastha Dubey
adubey7@[email protected]
650-725-2084
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
ECOG performance status of 0-2
Age ≥ 18 years old
Ability to understand and the willingness to personally sign the written IRB approved informed consent document
Estimated life expectancy of 12 weeks or longer

Exclusion

Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
Age \< 18 years old
Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
Diagnosis of interstitial pulmonary fibrosis
Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

What this trial measures

  • Dose limiting pulmonary and esophageal toxicity9 months

    Toxicities will be scored by the CTCAE v5.0 criteria. Specific toxicities evaluated are grade 2+ pneumonitis and grade 3+ esophagitis as well as other G3+ pulmonary, esophageal or cardiac toxicities that could be probably or definitely attributed to rT.